Sensus Healthcare (SRTS) Reports Prelim Q3 Revenue of Over $13M

Sensus Healthcare, Inc. (Nasdaq: SRTS) today reports preliminary 2022 fourth quarter and full year revenues.

Preliminary revenues for the three months ended December 31, 2022 are expected to exceed $13 million. For the full year 2022, revenues are expected to exceed $44 million, representing growth of approximately 60% over 2021. Fourth quarter 2022 revenues are expected to include more than $500,000 from the company’s aesthetics business. Sensus also announces it expects that both the fourth quarter and the full year will be profitable.

“We’re delighted to report topline momentum during the fourth quarter and to share our expectations for continued growth in revenues and profitability in 2023,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “Our robust marketing programs, combined with an expanded product offering and the opening of new customer channels, are expected to contribute to our growth trajectory.”

The company plans to continue adding to its domestic sales force and increase its trade show presence during 2023. Outside of the U.S., the company intends to expand geographic reach in both the EU and Latin America. It also plans to expand its product portfolio in the second half of 2023 with several submissions to the U.S. Food and Drug Administration expected to be made for new technologies.

Sensus Healthcare plans to announce 2022 fourth quarter and full year financial results and hold an investment community conference call after the close of the U.S. stock markets on February 9, 2023. Conference call details including participation instructions will be provided at a later date.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA maintains underperform ratings on six BDC stocks
• Vireo Growth completes acquisition of C21 Investments